New Studies, Regulatory Submissions, and Leadership Changes - Research Report on St. Jude Medical, Teva Pharmaceutical Industries, Avanir Pharmaceuticals, Novo Nordisk, and Trius Therapeutics

NEW YORK, June 10, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting St. Jude Medical, Inc. (NYSE: STJ), Teva Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR), Novo Nordisk A/S (ADR) (NYSE: NVO), and Trius Therapeutics, Inc. (NASDAQ: TSRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

St. Jude Medical, Inc. Research Report

On June 4, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that the US Food and Drug Administration (FDA) has given the Company approval to begin the EnligHTN IV Renal Denervation Study, the first trial using the EnligHTN Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure. According to the Company, renal denervation is a minimally invasive therapy that may provide a lasting reduction in blood pressure for patients with hypertension and are resistant to medications. It is a specialized ablation procedure that targets nerves along the renal arteries leading to the kidneys. This intentional disruption of the nerves may cause a decrease in systolic and diastolic blood pressure. Frank J. Callaghan, President of the St. Jude Medical Cardiovascular and Ablation Technologies Division, said, "Researching the treatment of hypertension is one example of the ongoing investments St. Jude Medical is making to deliver high-quality, innovative products, such as the EnligHTN Renal Denervation System, which aim to reduce health care costs and improve patient outcomes." The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/bf35_STJ]

Teva Pharmaceutical Industries Ltd. (ADR) Research Report

On June 3, 2013, Teva Pharmaceutical Industries Ltd. (ADR) (Teva) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that a Marketing Authorization may be issued in the European Union for Lonquex (XM22 lipegfilgrastim) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes). Dr. Michael Hayden, Teva's President of Global R&D and Chief Scientific Officer, said, "Effective prophylaxis against neutropenia and febrile neutropenia is a high priority for patients undergoing cytotoxic chemotherapy. This chemotherapy attacks rapidly dividing bone marrow cells and dramatically reduces the ability to fight off infection, which can have serious consequences for patients. Loquenex reduces the neutropenia that can lead to these consequences. We look forward to receiving final approval and being able to offer this medication to patients." The Full Research Report on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/e4ac_TEVA]

Avanir Pharmaceuticals, Inc. Research Report

On June 5, 2013, Avanir Pharmaceuticals, Inc. (Avanir) announced that the US Food and Drug Administration (FDA) has agreed to an expedited development pathway for their next-generation compound, AVP-786, requiring only a limited pre-clinical package as part of the Investigational New Drug (IND) application. AVP-786 is a novel investigational drug product consisting of a combination of deuterium modified dextromethorphan (a new chemical entity or NCE) and ultra-low dose quinidine, used as a metabolic inhibitor. Joao Stiffert, MD, Avanir's Chief Scientific Officer, said, "Avanir will be allowed to reference the extensive data generated during AVP-923 development programs in support of the AVP-786 IND and subsequent new drug application. This has the potential to substantially reduce the cost and time to market. We anticipate that we will be able to seamlessly integrate AVP-786 into our ongoing development programs in neuropathic pain, agitation in Alzheimer's disease and levodopa induced dyskinesia in Parkinson's disease." The Full Research Report on Avanir Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/22e9_AVNR]

Novo Nordisk A/S (ADR) Research Report

On May 31, 2013, Novo Nordisk A/S (ADR) announced the submission of marketing authorization applications for IDegLira, the combination product of insulin degludec (Tresiba), the once-daily new-generation basal insulin analogue, with an ultra-long direction of action, and liraglutide (Victoza), the once-daily human GLP-1 analogue, to the European Medicines Agency. IDegLira was developed for the treatment of type 2 diabetes. In other news, the Company initiated a share repurchase program on May 3, 2013. This program is part of the overall share repurchase program of up to (Danish Krone) DKK14 billion to be executed during a 12-month period starting January 31, 2013. The Full Research Report on Novo Nordisk A/S (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/f4ec_NVO]

Trius Therapeutics, Inc. Research Report

On June 3, 2013, Trius Therapeutics, Inc. (Trius) announced the appointment of Matthew Onaitis to the newly created role of General Counsel and Secretary of the Company. He previously served as Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc., where he led the legal, compliance and business development functions. Jeffrey Stein, President and Chief Executive Officer of Trius, said, "In particular, his background in completing transactions, managing corporate governance and commercial compliance programs and supporting regulatory and commercial operations will strengthen our management team as we prepare for commercialization of tedizolid in the United States, pending regulatory approval." The Full Research Report on Trius Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/1eb9_TSRX]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquires, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports